Key Points
- Adam Crystal sold 38,460 shares of Tango Therapeutics on April 15 at an average price of $25 for $961,500, reducing his stake to 112,622 shares (a 25.46% decrease).
- Those April sales were part of a series of disposals from February–April, amounting to roughly 170,500 shares and about $3.0 million in total proceeds.
- TNGX trades near $25 with a market cap of $3.57B and a consensus analyst rating of "Moderate Buy" with a target of $20.67; the company is a clinical‑stage biotech focused on synthetic lethality and DNA damage response targets.
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 38,460 shares of the business's stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $25.00, for a total transaction of $961,500.00. Following the completion of the transaction, the insider owned 112,622 shares in the company, valued at approximately $2,815,550. The trade was a 25.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Adam Crystal also recently made the following trade(s):
- On Wednesday, April 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.20, for a total transaction of $572,400.00.
- On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $20.11, for a total transaction of $241,320.00.
- On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The shares were sold at an average price of $15.00, for a total transaction of $303,765.00.
- On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65.
- On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.26, for a total transaction of $226,221.52.
Tango Therapeutics Stock Down 1.1%
TNGX stock opened at $25.04 on Friday. The firm has a market cap of $3.57 billion, a price-to-earnings ratio of -28.78 and a beta of 1.31. Tango Therapeutics, Inc. has a 12-month low of $1.03 and a 12-month high of $26.00. The company's fifty day simple moving average is $16.94 and its 200 day simple moving average is $12.03.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. Research analysts expect that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the stock. Canaccord Genuity Group initiated coverage on shares of Tango Therapeutics in a report on Thursday, April 2nd. They issued a "buy" rating and a $30.00 target price on the stock. Mizuho upped their price objective on shares of Tango Therapeutics from $19.00 to $20.00 and gave the company an "outperform" rating in a report on Wednesday, March 11th. Jefferies Financial Group reiterated a "buy" rating and set a $18.00 price objective on shares of Tango Therapeutics in a report on Thursday, March 5th. HC Wainwright upped their price objective on shares of Tango Therapeutics from $13.00 to $27.00 and gave the company a "buy" rating in a report on Friday, March 6th. Finally, Piper Sandler upped their price objective on shares of Tango Therapeutics from $11.00 to $14.00 and gave the company an "overweight" rating in a report on Friday, January 16th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Tango Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $20.67.
Check Out Our Latest Stock Report on TNGX
Hedge Funds Weigh In On Tango Therapeutics
Several institutional investors have recently made changes to their positions in TNGX. Global Retirement Partners LLC acquired a new position in shares of Tango Therapeutics during the fourth quarter valued at about $35,000. Dynamic Technology Lab Private Ltd raised its holdings in shares of Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company's stock valued at $35,000 after purchasing an additional 15,037 shares during the period. Legal & General Group Plc raised its holdings in shares of Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company's stock valued at $36,000 after purchasing an additional 1,640 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Tango Therapeutics by 148,800.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company's stock valued at $40,000 after purchasing an additional 4,464 shares during the period. Finally, ANTIPODES PARTNERS Ltd bought a new stake in shares of Tango Therapeutics during the fourth quarter worth about $40,000. Institutional investors and hedge funds own 78.99% of the company's stock.
Tango Therapeutics Company Profile
(
Get Free Report)
Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.
The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
